Veradigm Inc.

OTCPK:MDRX Stock Report

Market Cap: US$517.7m

Veradigm Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Don Trigg

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure1.5yrs

Recent management updates

Recent updates

Analysis Article • Feb 28

Veradigm (NASDAQ:MDRX) Is Doing The Right Things To Multiply Its Share Price

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Analysis Article • Nov 10

Veradigm (NASDAQ:MDRX) Might Have The Makings Of A Multi-Bagger

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
Analysis Article • Mar 06

Veradigm's (NASDAQ:MDRX) Returns On Capital Are Heading Higher

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...
Analysis Article • Feb 13

Is It Too Late To Consider Buying Veradigm Inc. (NASDAQ:MDRX)?

While Veradigm Inc. ( NASDAQ:MDRX ) might not be the most widely known stock at the moment, it saw significant share...
Analysis Article • Jan 22

Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate

Key Insights Veradigm's estimated fair value is US$35.1 based on 2 Stage Free Cash Flow to Equity Current share price...
Analysis Article • Jan 04

These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Dec 03

Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
Seeking Alpha • Sep 28

Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%

Allscripts Healthcare Solutions (NASDAQ:MDRX) reaffirmed its 2022 financial guidance, including $110M-$120M of free cash flow. Also, the company said its Veradigm data insights segment would have 6%-7% revenue growth and 10%-15% year-over-year adjusted EBITDA growth. During an investor day presentation earlier Wednesday, Allscripts (MDRX) management used the opportunity to showcase its competitive advantages and benefits for providers and payers. Despite the presentation, shares are down ~2% in Wednesday afternoon trading. Seeking Alpha's Quant Rating views Allscripts (MDRX) with high marks for profitability and momentum.
Analysis Article • Sep 17

Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?

Allscripts Healthcare Solutions, Inc. ( NASDAQ:MDRX ), is not the largest company out there, but it saw a double-digit...
Analysis Article • Aug 24

Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist

What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a...
Analysis Article • Jul 31

We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

CEO

Don Trigg (54 yo)

less than a year
Tenure

Mr. Donald D. Trigg, also known as Don, is CEO & Director of Veradigm LLC from September 2025. Mr. Trigg has been Chief Executive Officer of Veradigm Inc. since September 2, 2025 and also serves as it's Di...

Leadership Team

NamePositionTenureCompensationOwnership
Donald Trigg
Chief Executive Officer & Directorless than a yearno datano data
Christian Greyenbuhl
Chief Financial Officerless than a yearno datano data
Tehsin Syed
Chief Product & Technology Officerless than a yearno datano data
Steven Halper
Vice President of Investor Relationsless than a yearno datano data
Eric Jacobson
Senior VPless than a yearno data0.27%
$ 1.4m
Richard Elmore
Senior Vice President of Corporate Development & Strategy7.5yrsno datano data
Tally Baker
Chief Human Resources Officerno datano datano data
John Sage
Senior Vice President of U.S. Hospitals & Health Systems Sales11.6yrsno datano data
Elliot Bryant
Senior VP & General Manager for Classic Client Solutions Business Unit5.9yrsno datano data
John Mayr
Senior Vice President of Global Client Delivery Organization4.5yrsno datano data
Troy Tetzlaff
Senior Vice President of Revenue Operationsless than a yearno datano data
Divesh Singla
Managing Director of India Operationsless than a yearno datano data
0.7yrs
Average Tenure
49.5yo
Average Age

Experienced Management: MDRX's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Donald Trigg
Chief Executive Officer & Director1.5yrsno datano data
Louis Silverman
Independent Chairman1.4yrsno data0.0093%
$ 48.0k
Bruce Felt
Independent Director1.3yrsno data0.0080%
$ 41.3k
Carol Zierhoffer
Lead Independent Director5.9yrsUS$531.39k0.077%
$ 400.8k
David Stevens
Independent Director10.2yrsUS$527.01k0.068%
$ 353.9k
Vinit Asar
Independent Director1.4yrsno data0.0093%
$ 48.0k
Kim Franks
Member of Advisory Boardno datano datano data
Jeanne Armstrong
Member of Advisory Boardno datano datano data
Geoff Caplea
Member of Advisory Boardno datano datano data
Laura Kohlhagen
Member of Advisory Boardno datano datano data
Debbie McKay
Member of Advisory Boardno datano datano data
Ramanujam Venugopalan
Member of Advisory Boardno datano datano data
1.5yrs
Average Tenure
64.5yo
Average Age

Experienced Board: MDRX's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 21:22
End of Day Share Price 2026/07/08 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Veradigm Inc. is covered by 29 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Matthew GillmorBaird
Lawrence MarshBarclays